It is expected that generic competition will take place in earnest in the Pelubi market, a osteoarthritis treatment worth 30 billion won per year. Following Youngjin Pharmaceutical, which launched generic alone, Huons and Chong Kun Dang are predicting their entry into the market.

Daewon Pharmaceutical, which faces the challenge of generic, is in a situation where it is confronting each other by releasing follow-up drugs such as original formulation change and salt change products.

◆Generic for exclusivity of first generics ends
According to the pharmaceutical industry on the 6th, the period of Youngjin's Pelubi will end on the 25th of this month. Phelps is the first generic